Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05535192 · ClinicalTrials.gov registry record · NA
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
A NA study of Breast Cancer and Breast Cancer Female, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 270
- Enrollment target
- 3
- Study locations
NCT05535192: Recruiting NA study of Breast Cancer and Breast Cancer Female, sponsored by Dana-Farber Cancer Institute.
NCT05535192 is a NA study of Breast Cancer and Breast Cancer Female that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 270 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05535192, a NA study of Breast Cancer and Breast Cancer Female, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 270 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research is being done to assess whether an exercise intervention with protein intake support vs a health education and support program will make it easier for women age 65 or older who are receiving chemotherapy for breast cancer to receive all of their planned chemotherapy according to schedule and at the planned dose.
Primary Outcome
Review of electronic medical records to discern chemotherapy dose received versus prescribed.
Conditions Studied
Interventions
- BEHAVIORAL THRIVE
- BEHAVIORAL Health Education Support Program
Study Locations (3)
Massachusetts
- Dana Farber Cancer Institute - Boston
Ohio
- Case Western Reserve University/University Hospitals Cleveland - Cleveland
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2023-03-20 |
| Est. Completion | 2027-02-01 |
| Phase | NA |
What NCT05535192 shows while recruiting
NCT05535192 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (90% lower).
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which THRIVE is the first listed.
NCT05535192 reports a single indexed study location in Massachusetts, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05535192 about?
NCT05535192 is a clinical study titled "TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients". This research is being done to assess whether an exercise intervention with protein intake support vs a health education and support program will make it easier for women age 65 or older who are receiving chemotherapy for breast cancer to receive all of their planned chemotherapy according to schedu...
What is the current status of trial NCT05535192?
This trial is currently recruiting. It is a NA study. The enrollment target is 270 participants. The study started on 2023-03-20. Estimated completion is 2027-02-01.
What conditions does trial NCT05535192 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Cancer Female, Stage II Breast Cancer, Stage III Breast Cancer, Stage I Breast Cancer.
What interventions are being tested in trial NCT05535192?
The interventions under investigation include: THRIVE (BEHAVIORAL), Health Education Support Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT05535192?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05535192 being conducted?
This trial has 3 study locations across Massachusetts, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05535192's enrollment target sits among peer trials
270 304th of 1224 higher than 918 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI